Dear Sir, Please find the attached REVISED OURCOME OF THE MEETING held on 27-11-2025. Kindly take the note of the same. Director
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories Ltd has informed the BSE about two key decisions from its board meeting. First, the Board authorized Mr. Narayan Kutty Menon, Whole-time Director & CEO (DIN 01111297), to identify buyers and negotiate terms for the proposed sale of the company's factory premises. Shareholders had already approved this sale through a Postal Ballot Special Resolution on November 11, 2025, under Section 180(1)(a) of the Companies Act. Second, the Board appointed Ms. Falguni Kumawat (ICSI Membership No. ACS-78132) as the new Company Secretary and Compliance Officer, effective December 1, 2025. She has 16 years of experience in secretarial, legal, and finance functions. The meeting ran from 3:30 p.m. to 5:30 p.m.
The factory sale is a significant asset divestment that could reshape the company's operations and unlock value, depending on the sale price realized. The new Company Secretary appointment is a routine compliance move and does not materially affect shareholders. Investors should watch for further updates on the factory sale terms and proceeds.